Xxxxx Dx Sample Clauses

Xxxxx Dx. Xxxxxxxx
Sample 1
Xxxxx Dx. Xxxxxxx Xxxxxxxx and Rxxxxxx Xxxxx shall immediately appointed to serve on the Board of Directors of GULF as President and CEO, Director and Chief Science Officer, Director and Chief Financial Officer respectively.
Sample 1
Xxxxx Dx. Xxxxxxxx Please acknowledge your agreement to the above letter Amendment by signing below where indicated. BioMedicines, Inc. By: /s/ S X Xxxxx Name: SX Xxxxx, M.D. Title: Chief Executive Officer 24 February 2000 BioMedicines, Inc. (BMI) and Protein Delivery, Inc. (PDI) have executed an agreement to explore the feasibility of developing an oral formulation of omega interferon. PDI will utilize patented technology to [*] to produce one of two general structures: After generating up to three different OFP or OPF structural classes representative structures from each class will be examined with the BM8233 commercial assay for quantitating omega interferon. BMI will supply the assay and methodology. PDI will establish the assay in its facilities. In addition, these representative structures will be assayed for bioactivity. Currently, the two companies intend to develop the A549-EMCV bioassay utilizing cells and virus obtained from the U.S. ATCC and methods to be developed by the two companies. It is anticipated, however, that the assay system will be established in a Biohazard 3 capable laboratory extrinsic to both companies. The most probable sites are the University of Utah and Duke University. Final selection of a bioassay laboratory will be made at a later date. If a suitable OFP or OPF structure can be identified which is both measurable and active, the molecule will be scaled up sufficiently to permit testing of oral absorption. Currently, PDI is utilizing a rodent model developed collaboratively with Duke University. In addition, BMI is now negotiating with XTL Biotherapeutics regarding the XTL Trimeris biosystem. The overview described above is necessarily brief and will be expanded during the course of detailed planning and execution. Subsequent, more detailed plans can be made available as they are developed. Currently, PDI and BMI expect to pursue the activity-timetable shown on the following page. Bio-Medicines, Inc. (BMI) and Durect, Inc. (DI) have a non-binding agreement to explore the feasibility of developing a sustained release formulation of omega interferon. DI will utilize patented technology to produce both a new formulation of unmodified omega interferon suitable for inclusion in the Duros® technology. DI has certain rights under license from the Alza Corporation. Currently the rights to develop a [*] will need to be obtained from Alza. BMI and DI have agreed upon a structure for the feasibility, development and subsequent commercializati...
Sample 1

Related to Xxxxx Dx

  • Xxxxx X Xxxxxxxx ------------------------ Xxxxx X. Xxxxxxxx

  • Xxxxx, Xx Xxxxxx X.

  • Xxxxxx X Xxxxxxxx ----------------------------- Xxxxxx X. Xxxxxxxx

  • Xxxxx Name: Xxxxxxx X. Xxxxx Title: Assistant Treasurer

  • Xxxxxx, P A., special counsel for IMC, in IMC's capacity as both Seller and Servicer under the Sale and Servicing Agreement, and/or Xxxxx & Xxxxxx LLP shall have furnished to the Underwriters their written opinion or opinions, addressed to the Underwriters and the Depositor and dated the Closing Date, in form and substance satisfactory to the Underwriters, to the effect that:

  • Xxxxxx Failure by either party to take action or assert any right under this Contract will not be deemed a waiver of such right in the event of the continuation or repetition of the circumstances giving rise to such right. Any such waiver must be in writing and signed by the parties.

  • Xxxxx Xxxx Purchase Order and Sales Contact Email 2 Purchase Order and Sales Contact Phone 2 3 Company Website 2 4 Entity D/B/A's and Assumed Names 5 Primary Address 2 6 Primary Address City 7 Primary Address State 2 8 Primary Address Zip 9 Search Words Identifying Vendor Certification of Vendor Residency (Required by the State of Texas)

  • Xxxxx, P C. shall be the closing attorney if Property is in the Greater Augusta or Aiken area. XxXxxxxx Xxxxx, P.C. shall be the closing attorney if Property is in the Savannah area, and Xxxxxxx Xxxxxxx shall be the closing attorney if Property is in the Statesboro area, and Xxxxxxxx Xxxxxxxxxx Law Firm shall be the closing attorney if Property is in the Greenwood area. Buyer agrees Seller will schedule closing date and time in accordance with Section 4 E (a) of the Agreement. Seller will notify Buyer of the date and time of closing. Failure to close home by Closing Date stated in Paragraph 3, page 1, of the Agreement will, at Seller’s option, result in termination of the Agreement, and forfeiture of the xxxxxxx money, Construction Deposits and any extras deposits. In addition, any remaining balance of money owed for extras ordered by the Buyer shall be immediately due and payable.

  • Xxxxxx Xxxx Purchase Order and Sales Contact Email 2 Purchase Order and Sales Contact Phone 2 3 Company Website 2 4 Entity D/B/A's and Assumed Names 5 Primary Address 2 Primary Address City 7 Primary Address State 2 8 Primary Address Zip 9 Search Words Identifying Vendor 0 Certification of Vendor Residency (Required by the State of Texas)

  • Xxxxxx, Xx Xxxxxx X. Xxxxxxx

Most Referenced Clauses

Most Referenced Definitions